Lab Tested
British Dragon Testabol Testosterone 250 and 100 mg Vials
Out of stock
Injection · 50 mg · vial
British Dragon GHK-CU is a copper-binding tripeptide of glycine, histidine and lysine, supplied as a research powder in a 50 mg vial for laboratory work on collagen synthesis and skin repair. No regulator has approved it for human use.
GMP-manufactured, each batch HPLC-verified with the Certificate of Analysis on file. GHK-CU for sale with international shipping at GenXXLGear.
British Dragon GHK-CU is the copper tripeptide GHK-Cu: the sequence glycine-histidine-lysine bound to copper in a 1:1 complex, supplied as a research powder in a 50 mg vial. The GHK sequence occurs in the alpha-2(I) chain of type I collagen and is released when tissue is damaged, which is why it is studied for collagen synthesis and skin repair rather than as a hormone. No regulator has approved it for human use. The same substance from another line is described on the Axiolabs GHK-CU page.
The research literature describes the peptide as supporting collagen, elastin and glycosaminoglycan synthesis, encouraging dermal fibroblasts and modulating the matrix metalloproteinases that break tissue down. It also has documented antioxidant and anti-inflammatory activity, and it is described as promoting blood vessel and nerve growth in experimental models. Human data is confined to topical creams used over about twelve weeks, where skin density and the appearance of wrinkles were the endpoints; injected human trials are not presented in the sources. Human half-life has not been established, and this page states that rather than guessing. The other repair peptides in the line are BPC-157 and TB-500, which act through different mechanisms. No official listing of GHK-Cu on the WADA prohibited list could be found, which is a lack of data rather than a statement that it is allowed.
Add bacteriostatic water down the wall of the vial and swirl gently instead of shaking it, because the peptide chain is fragile. A 50 mg vial with 2 to 5 ml of solvent gives roughly 10 to 25 mg per ml, which is the reconstitution example published for the neighbouring copper peptide line. Keep the powder cold and dry before use, hold the dissolved solution at 2-8 C, and do not freeze it. Amounts quoted by suppliers are research references, because no validated human dosing exists for this compound. A separate solvent is listed as Bacteriostatic Water, and the pentadecapeptide repair option is on the BPC 157 page.
For laboratory research only. Consult a healthcare professional before use. Figures quoted are community protocols and research references, not a prescription.
| Trade Name | GHK-CU |
| Generic Name | Copper tripeptide-1 (GHK-Cu) |
| Manufacturer | British Dragon |
| Dosage | 50 mg per vial |
| Package | Single vial, research powder |
| Drug Class | Copper-binding tripeptide, research peptide |
| Administration | Research use after reconstitution |
| Storage | Powder cold and dry; solution 2-8 C, do not freeze |
| Prescription Status | Research use only; not for human use |
| Verification | GMP production, third-party HPLC, COA per batch |
| Shipping | International 4-10 days |
Before you ask
It is the copper tripeptide GHK-Cu, the sequence glycine-histidine-lysine bound to copper in a 1:1 complex, supplied as a 50 mg research powder in a vial. The GHK sequence occurs in the alpha-2(I) chain of type I collagen and is released when tissue is damaged. It is studied for collagen synthesis and skin repair, and no regulator has approved it for human use.
Add bacteriostatic water down the wall of the vial and swirl gently rather than shaking it, because the peptide chain is fragile. A 50 mg vial with 2 to 5 ml of solvent gives roughly 10 to 25 mg per ml, which is the reconstitution example published for the neighbouring copper peptide line. Keep the powder cold and dry, hold the solution at 2-8 C, and do not freeze it.
The human data that exists comes from topical creams used over roughly twelve weeks, where skin density and the appearance of wrinkles were measured. Injected human trials are not presented in the sources, and no human half-life has been established for the peptide. That makes the vial a research material rather than a preparation with a known clinical profile, and this page describes it that way.
No clinical side-effect profile can be written from the sources, and this page will not invent one. Reports of headaches above three to four milligrams per day come from online protocol discussions rather than from clinical data, so they are recorded here as unverified. The material is sold for laboratory work and is not approved for human use, so any use outside a research setting sits outside its intended purpose.
No official listing of GHK-Cu on the WADA prohibited list could be found in the sources consulted, and that absence of data is not the same as permission. Athletes subject to testing should treat an unlisted research peptide with caution rather than as an allowed substance, and the federation or anti-doping body is the authority to ask.
The 50 mg vial is listed on this page. Availability is shown on the product page, which also takes an email address for restock notices when the item is out. Shipping details are in the product data: international delivery with discreet plain packaging, and one to two business days of handling once an order is placed.
Be the first to share your experience with British Dragon GHK-CU 50 mg Lyophilized Copper Peptide Vial
Log in to write a reviewComplete the cycle
Lab Tested
Out of stock
Out of stock
Out of stock